Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Precision biosciences | Mind Blowing Facts

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral

Here's a roundup of top developments in the biotech space over the last 24 hours:

Why Precision BioSciences Shares Are Surging Today

Why Precision BioSciences Shares Are Surging Today

Precision BioSciences Inc (NASDAQ:DTIL) has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG (NYSE:NVS) Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a "safe harbor" location in the genome as a potential one-time…

BMO Sees 'Differentiated Gene Editing Platform' For This Small-Cap Stock

BMO Sees 'Differentiated Gene Editing Platform' For This Small-Cap Stock

BMO Capital Markets initiated the coverage on Precision BioSciences Inc (NASDAQ:DTIL) with an Outperform rating and a price target of $7. The analyst said the thesis is based on: The company's proprietary gene-editing platform, whose mechanism is differentiated in a CRISPR-dominated space, offers several advantages. A diversified pipeline. Asymmetric risk/reward skewed to the upside.…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2022

Precision BioSciences Highlights Interim Data From Allogeneic CAR T Programs In Blood Cancer Patients

Precision BioSciences Inc (NASDAQ:DTIL) shared new interim data from the Phase 1/2a study of PBCAR0191 for the patient population with aggressive lymphomas. The data demonstrated that PBCAR0191 produced high clinical response rates in CAR T relapsed patients who received a median of five prior lines of therapy. Evaluable subjects in the study had…

Precision BioSciences Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Precision BioSciences (NASDAQ:DTIL) reported Q1 sales of $3.32 million. Earnings fell to a loss of $28.17 million, resulting in a 26.37% decrease from last quarter.

Preview: Precision BioSciences's Earnings

Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Precision BioSciences will report an earnings per share (EPS) of $-0.55.

inkl

Read news from The Economist, FT, and more,
with one subscription

Looking Into Precision BioSciences's Return On Capital Employed

Looking Into Precision BioSciences's Return On Capital Employed

Precision BioSciences (NASDAQ:DTIL) brought in sales totaling $6.34 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 97.62%, resulting in a loss of $22.29 million.

Recap: Precision BioSciences Q4 Earnings

Recap: Precision BioSciences Q4 Earnings

Precision BioSciences (NASDAQ:DTIL) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Preview: Precision BioSciences's Earnings

Preview: Precision BioSciences's Earnings

Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate that Precision BioSciences will report an earnings per share (EPS) of $-0.47.

Tiziana Life Shares Rise On Encouraging Data From Intranasal Foralumab In Multiple Sclerosis Patient

Tiziana Life Shares Rise On Encouraging Data From Intranasal Foralumab In Multiple Sclerosis Patient

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported clinical data in a patient with Secondary Progressive Multiple Sclerosis (SPMS) following six months of treatment with intranasally administered foralumab. In addition to being well-tolerated, both biological and clinical improvements were seen in the patient using Tiziana's immunotherapy technology, which overcame the challenge of delivering foralumab…

1

Organisations

FreeportMcMoRan

Eli Lilly And Co

Keefe Bruyette & Woods

BMO Capital Markets

Ollie Bargain Outlet

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Sickle Cell Disease

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play